Skip to main content
logo
Concord Drugs Limited (BOM:538965)
India flag India · Delayed Price · Currency is INR
67.93
-2.07 (-2.96%)
At close: Jul 27, 2026

Concord Drugs Financials Overview

Millions INR. Fiscal year is Apr - Mar.

Revenue & Profits
Chart
Fiscal YearTTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingMar '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Revenue
787.37787.37452.45449.25520.81590.43
Revenue Growth
74.02%74.02%0.71%-13.74%-11.79%14.77%
Gross Profit
110.91110.9195.98111.92104.85164.73
Operating Income
31.5331.5327.0424.8729.4639.14
Net Income
10.5510.553.364.729.8615.94
Earnings Per Share
0.950.950.340.471.061.82
EPS Growth
182.57%182.57%-28.47%-55.57%-41.87%-51.47%

Cash & Debt
Chart
Fiscal YearCurrentFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingMar '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Cash & Investments
7.517.512.251.760.990.65
Total Debt
145.08145.08192.44175.19169.65164.34
Net Cash (Debt)
-137.58-137.58-190.18-173.42-168.65-163.69
Net Cash Growth
------
Net Cash Per Share
-12.39-12.39-19.02-17.34-18.11-18.72

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingMar '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Operating Cash Flow
-67.66-67.6637.227.9216.637.74
Capital Expenditures
-11.67-11.67-23.33-10.18-8.57-24.56
Free Cash Flow
-79.33-79.3313.89-2.268.06-16.82
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingMar '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Gross Margin
14.09%14.09%21.21%24.91%20.13%27.90%
Operating Margin
4.00%4.00%5.98%5.54%5.66%6.63%
Pretax Margin
1.87%1.87%1.53%1.40%2.40%3.81%
Profit Margin
1.34%1.34%0.74%1.05%1.89%2.70%
FCF Margin
-10.08%-10.08%3.07%-0.50%1.55%-2.85%

Valuation
Chart
Fiscal YearCurrentFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingJul '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
PE Ratio
72.5287.7092.4574.4725.9515.91
P/FCF Ratio
--22.37-31.71-
PS Ratio
1.151.180.690.780.490.43